BeiGene, Ltd. (NASDAQ:BGNE) Receives Average Recommendation of “Moderate Buy” from Analysts

BeiGene, Ltd. (NASDAQ:BGNE) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $253.69.

Several research analysts have recently weighed in on the stock. JMP Securities initiated coverage on shares of BeiGene in a report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price target for the company. Morgan Stanley reiterated an “overweight” rating and set a $300.00 price objective on shares of BeiGene in a report on Tuesday, December 3rd. StockNews.com downgraded shares of BeiGene from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. JPMorgan Chase & Co. upped their target price on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, October 22nd. Finally, TD Cowen boosted their price target on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th.

BeiGene Stock Performance

BGNE stock opened at $181.62 on Wednesday. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. BeiGene has a twelve month low of $126.97 and a twelve month high of $248.16. The business’s fifty day moving average is $200.00 and its 200-day moving average is $188.12. The company has a market cap of $17.71 billion, a P/E ratio of -22.04 and a beta of 0.57.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. During the same period last year, the company earned $2.01 earnings per share. The business’s revenue was up 28.2% compared to the same quarter last year. Equities research analysts forecast that BeiGene will post -5.64 EPS for the current year.

Insiders Place Their Bets

In other news, insider Xiaodong Wang sold 41,760 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $186.90, for a total value of $7,804,944.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO John Oyler sold 6,175 shares of the stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total transaction of $1,433,958.50. The disclosure for this sale can be found here. Insiders sold 1,131,622 shares of company stock worth $212,520,787 over the last three months. Insiders own 7.43% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BGNE. Blue Trust Inc. increased its holdings in BeiGene by 156.3% in the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock valued at $28,000 after purchasing an additional 75 shares during the period. Raymond James & Associates increased its stake in shares of BeiGene by 0.4% in the second quarter. Raymond James & Associates now owns 21,275 shares of the company’s stock valued at $3,035,000 after buying an additional 76 shares during the period. Truist Financial Corp raised its position in shares of BeiGene by 10.1% during the second quarter. Truist Financial Corp now owns 1,521 shares of the company’s stock worth $217,000 after acquiring an additional 140 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of BeiGene in the third quarter worth approximately $36,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in BeiGene by 0.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 97,895 shares of the company’s stock valued at $21,978,000 after acquiring an additional 266 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.